会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 91. 发明申请
    • POLYVINYLIDENE FLUORIDE COMPOSITES AND METHODS FOR PREPARING SAME
    • 聚亚苄基氟化物复合材料及其制备方法
    • WO2003007314A1
    • 2003-01-23
    • PCT/US2002/021754
    • 2002-07-10
    • HYPERION CATALYSIS INTERNATIONAL, INC.
    • NIU, ChunmingNGAW, LeinFISCHER, AlanHOCH, Robert
    • H01B1/24
    • B82Y10/00B82Y30/00C08J3/212C08J2327/16C08K7/24H01B1/24Y10S977/742Y10S977/788C08L27/16
    • An electrically conductive composite comprising a polyvinylidene fluoride polymer or copolymer and carbon nanotubes is provided. Preferably, carbon nanotubes may be present in the range of about 0.5-20% by weight of the composite. The composites are prepared by dissolving the polymer in a first solvent to form a polymer solution and then adding the carbon nanotubes into the solution. The solution is mixed using an energy source such as a sonicator or a Waring blender. A precipitating component is added to precipitate out a composite comprising the polymer and the nanotubes. The composite is isolated by filtering the solution and drying the composite. The composites are also prepared by mixing or dispersing carbon nanotubes in polymer emulsion using an energy source such as a Waring blender. The liquid in the mixture is then evaporated to obtain the composite comprising the polymer and the nanotubes.
    • 提供了包含聚偏二氟乙烯聚合物或共聚物和碳纳米管的导电复合材料。 优选地,碳纳米管可以以该复合材料的约0.5-20重量%的范围存在。 通过将聚合物溶解在第一溶剂中以形成聚合物溶液,然后将碳纳米管加入到溶液中来制备复合材料。 使用诸如超声波发生器或Waring混合器的能量源将溶液混合。 加入沉淀组分以沉淀出包含聚合物和纳米管的复合材料。 通过过滤溶液并干燥复合物来分离复合物。 复合材料还可以通过使用诸如Waring混合器的能量源将碳纳米管混合或分散在聚合物乳液中来制备。 然后将混合物中的液体蒸发,得到包含聚合物和纳米管的复合材料。
    • 93. 发明申请
    • METHOD FOR SYNTHESIS OF HYDROXYAPATITE, AND HYDROXYAPATITE COMPLEX AND METHOD FOR PREPARING THE SAME
    • 羟基脂肪酸合成方法及羟基磷酸酯复合物及其制备方法
    • WO00058209A1
    • 2000-10-05
    • PCT/JP1999/001544
    • 1999-03-26
    • A61K6/06A61L27/12C01B25/32
    • A61K6/033A61L27/12C01B25/322Y10S977/773Y10S977/775Y10S977/788Y10S977/904Y10S977/919Y10T428/2982Y10T428/2991Y10T428/2998
    • A method for synthesizing a hydroxyapatite (HAp), characterized in that it comprises dispersing a calcium hydroxide (H3PO4) powder in a aqueous solution of phosphoric acid (Ca(OH)2) to thereby prepare a raw material mixture slurry, and applying a shearing force and a compression force resulting from the centrifugal force of a mechanically rotating body to the resulting slurry for performing a mechanochemical grinding treatment of the raw material mixture and effecting a reaction between the above-mentioned phosphoric acid and calcium hydroxide components at ordinary temperature and under atmospheric pressure, to thereby obtain a microcrystal powder of hydroxyapatite. The present method can be used for producing a microcrystal powder of hydroxyapatite having a fine and uniform diameter directly, in a single process, with ease, with a short production time, at ordinary temperature and under atmospheric pressure.
    • 一种羟基磷灰石(HAp)的合成方法,其特征在于,包括将氢氧化钙(H 3 PO 4)粉末分散在磷酸(Ca(OH)2)的水溶液中,由此制备原料混合物浆料,并施加剪切 力和由机械旋转体的离心力产生的压缩力与所得到的浆料进行原料混合物的机械化学研磨处理,并在常温和低于下述条件下进行上述磷酸和氢氧化钙组分之间的反应 大气压,从而得到羟基磷灰石的微晶粉末。 本方法可以在常规温度和大气压下,以简单的生产时间,在单一工艺中直接制造具有细直径均匀直径的羟基磷灰石微晶粉末。
    • 94. 发明申请
    • CORE-SHELL TECTODENDRIMERS
    • 核心TECTODENDRIMERS
    • WO00049066A1
    • 2000-08-24
    • PCT/US2000/003773
    • 2000-02-15
    • C08G69/00C08G69/02C08G69/04C08G69/48C08G81/00C08G83/00C08L77/06
    • C08G83/003C08G69/02C08G69/04C08G69/48Y10S424/16Y10S977/754Y10S977/788Y10S977/835
    • Core-shell tecto(dendrimers) useful in biomedicine, pharmaceuticals, personal care products, and in other ways analogous to the known uses for dendrimers, hypercomb branched polymers, and other dendritic polymers are the reaction product of a core dendritic polymer molecule having a plurality of terminal functional groups of a first type which are not reactive with each other, and a plurality of shell dendritic polymer molecules having a plurality of terminal functional groups of a second type which are not reactive with each other, but which are reactive with the terminal functional groups of the first type. Each of the shell dendritic polymer molecules is chemically bonded to the core dendritic polymer molecule by a reaction of at least one of the terminal functional groups of the second type with at least one of the terminal functional groups of the first type.
    • 可用于生物医学,药物,个人护理产品的核壳结构(树枝状大分子),以及类似于已知用于树枝状大分子,超支化支化聚合物和其它树枝状聚合物的其它方式是具有多个核心树枝状聚合物分子的反应产物 不具有反应性的第一种类型的末端官能团,以及具有多个不具有反应性但与末端反应性的第二类型的末端官能团的多个壳状树枝状聚合物分子 第一类功能组。 每个壳树枝状聚合物分子通过第二类型的至少一个末端官能团与至少一个第一类型的末端官能团的反应与核心树枝状聚合物分子化学键合。
    • 100. 发明申请
    • CONTROLLED RELEASE BIODEGRADABLE MICRO- AND NANOSPHERES CONTAINING CYCLOSPORIN
    • 受控释放的生物可降解的含有CYCLOSPORIN的微球和纳米磷
    • WO1996031202A1
    • 1996-10-10
    • PCT/IE1996000017
    • 1996-04-02
    • ELAN CORPORATION, PLC
    • ELAN CORPORATION, PLCRAMTOOLA, Zebunnissa
    • A61K31/13
    • A61K38/13A61K9/1647Y10S977/788Y10S977/795Y10S977/904Y10S977/915Y10S977/931
    • A controlled release pharmaceutical formulation which comprises cyclosporin entrapped in a biodegradable polymer to form microspheres or nanospheres such that the cyclosporin is substantially in an amorphous state and the biodegradable polymer comprises greater than 12.5 % w/w poly(lactide). The biodegradable polymer is suitably poly-D,L-lactide or a blend of poly-D,L-lactide and poly-D,L-lactide-co-glycolide. Additionally, an enteric coating can be applied to the microspheres or nanospheres or to the oral dosage form incorporating the microspheres or nanospheres to protect the formulation while it passes through the stomach. A particularly suitable formulation comprises 50 % w/w cyclosporin-loaded 80:20 blend of poly-D,L-lactide-co-glycolide to poly-D,L-lactide micro- and/or nanospheres. This formulation has the combined properties of nearly complete but relatively slow release of cyclosporin within 8 hours and is useful for targeting cyclosporin to the small intestine when administered orally.
    • 一种控释药物制剂,其包含环包埋在可生物降解聚合物中以形成微球体或纳米球体的环孢菌素,使得环孢菌素基本上处于非晶状态,生物可降解聚合物包含大于12.5%w / w的聚(丙交酯)。 生物可降解聚合物适宜为聚-D,L-丙交酯或聚-D,L-丙交酯和聚-D,L-丙交酯 - 共 - 乙交酯的共混物。 此外,肠溶衣可以应用于微球体或纳米球体或结合微球体或纳米球体的口服剂型,以在制剂通过胃部时保护制剂。 一种特别合适的制剂包含50%w / w的环孢菌素负载的聚-D,L-丙交酯 - 共 - 乙交酯的80:20共混物与聚-D,L-丙交酯微米和/或纳米球。 该制剂具有在8小时内几乎完全但相对缓慢释放环孢菌素的组合性质,并且用于口服给药时将环孢菌素靶向小肠。